Clinical Trials

Contemporary randomized clinical trials assessing invasive CV interventions are often small with short follow-up and limited power to identify large treatment effects, according to a study published in JAMA Internal Medicine.

NCI has supported assessment of health-related quality of life in cancer clinical trials for approximately 30 years.

The FDA increasingly is using surrogate endpoints to support approval of cancer drugs, according to results of a retrospective review in a research letter published in JAMA Internal Medicine.

Throughout history, crisis situations often have forced provisional changes that, upon further reflection, have been deemed worthy of permanent institution.

With the rise of the novel coronavirus in the United States, it is important for hepatologists and gastroenterologists to know how other practices are dealing with the impact of COVID-19. With nationwide shutdowns, medical institutions and practices are finding difficulties in seeing patients and researching drugs.

Participating in clinical trials is an incredibly satisfying way to expand your fund of knowledge, experience and suite of services to offer your wonderful patients. So many of our patients still have unmet needs despite our current approved offerings. Participating in clinical trials is a brilliant way to bring cutting-edge approaches to your deserving patients.

I am often asked by other ophthalmologists: “How do I get started working with industry?” My answer is always the same: Start by serving as an investigator in an industry-sponsored clinical trial. That is how I began 42 years ago, and it is still the best pathway for a clinician to initiate collaboration with our industry-based colleagues. Most are aware that I am a strong supporter of the virtuous effects of the so-called innovation cycle, and the innovation cycle in ophthalmology requires the engagement of a practicing ophthalmologist at every stage. A few thoughts on how to initiate engagement with industry as a clinical investigator.

Hosting clinical trials has benefits, such as allowing physicians to offer cutting-edge technologies and therapies to their patients and increasing practice marketing opportunities and revenue, but the amount of time and manpower involved, as well as the arduous process of achieving all necessary certifications, can be underestimated.

Bias among some health care and research professionals could partly explain persistent racial disparities in cancer clinical trial participation, according to study results published in Cancer.

Large randomized controlled trials comparing the treatment of Dupuytren’s contractures by needle fasciotomy and limited fasciectomy are feasible, according to results of a recently published study.